Visit http://indiaer.blogspot.com/ for complete details Jubilant Lifesciences (Rating – Buy; Target Price – Rs436)
Topline is expected to grow by 9.4% YoY to Rs10.2bn on the back of some big contracts.
EBIDTA margins are expected to be pressurized marginally to 19.2% on the basis of increased
initial expenditure, mostly on the staff expenses side, to facilitate the big contracts. However it
is expected to improve, going ahead.
We expect the adjusted PAT to grow by 43% on a YoY basis to Rs975mn.
No comments:
Post a Comment